Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elevated Type I Interferon Signaling Defines the Proliferative Advantage of ARF and p53 Mutant Tumor Cells.

Molecular and cellular biology - 1 Jan 2025

Mabry Alex, Kuzmicki Catherine E, O'Brien Angelina, Maggi Leonard B, Weber Jason D

Abstract excerpt

The tumor suppressors p53 and ARF collaborate to prevent unwarranted cell proliferation and as such are two of the most frequently mutated genes in human cancer. Concomitant loss of functional p53 and ARF leads to massive gains in cell proliferation and transformation and is often observed in some of the most aggressive human cancer subtypes. These phenotypic gains are preceded by increased type I interferon...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aza Compounds
Share to Azetidines
Share to Interferon Type I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 1

Share to Nitriles

Share to Purines

Share to Pyrazoles

Share to STAT1 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 40351125
DOI: 10.1080/10985549.2025.2497817
PMCID: PMC12136988

Genes

JAK1
STAT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elevated Type I Interferon Signaling Defines the Proliferative Advantage of ARF and p53 Mutant Tumor Cells.PMID 40351125Read ↗

Elevated type I interferon signaling defines the proliferative advantage of ARF and p53 mutant tumor cellsSemantic proximity Read ↗

ARF and p53 coordinate tumor suppression of an oncogenic IFN-β-STAT1-ISG15 signaling axis.Semantic proximity Read ↗

Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.Semantic proximity Read ↗

Proto-oncogene FBI-1 Represses Transcription of p21CIP1 by Inhibition of Transcription Activation by p53 and Sp1Semantic proximity Read ↗

Stat1 Phosphorylation Determines Ras Oncogenicity by Regulating p27Kip1Semantic proximity Read ↗

Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells.Semantic proximity Read ↗

Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms.Semantic proximity Read ↗

IRF1 Mediates Growth Arrest and the Induction of a Secretory Phenotype in Alveolar Epithelial Cells in Response to Inflammatory Cytokines IFNγ/TNFα.Semantic proximity Read ↗

Essential Role for Mnk Kinases in Type II Interferon (IFNγ) Signaling and Its Suppressive Effects on Normal HematopoiesisSemantic proximity Read ↗

ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon.Semantic proximity Read ↗

Patients with STAT1 gain-of-function mutations display increased IFNα-induced T cell apoptosis and upregulation of interferon signature that are responsive to ruxolitinib treatment.Semantic proximity Read ↗

Function and mechanism by which interferon regulatory factor-1 inhibits oncogenesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.